United Therapeutics Corporation (NASDAQ:UTHR) Q1 2026 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2026 Earnings Call Transcript May 6, 2026United Therapeutics Corporation misses on earnings expectations.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,630,000 | $1,559,537,400 | +1% | 15.34% |
| 2. | Renaissance Technologies Jim Simons | 1,787,019 | $1,059,666,527 | -7% | 1.66% |
| 3. | AQR Capital Management Cliff Asness | 826,226 | $486,424,477 | -36% | 0.22% |
| 4. | Deerfield Management James E. Flynn | 457,000 | $270,991,860 | +8% | 3.2% |
| 5. | Citadel Investment Group Ken Griffin | 360,643 | $213,854,086 | +93% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | $331.32 | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | $684.36 | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | $631.00 | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | $385.05 | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | $390.72 | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $572.36 | 120 | $68,683.60 | 40,513 | 2026-05-19 | Filing | |
| $571.24 | 562 | $321,035.92 | 40,633 | 2026-05-19 | Filing | |
| $570.35 | 1,099 | $626,815.42 | 41,195 | 2026-05-19 | Filing | |
| $569.42 | 1,393 | $793,198.72 | 42,294 | 2026-05-19 | Filing | |
| $568.46 | 1,640 | $932,275.88 | 43,687 | 2026-05-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,399,649 | $3,201,883,611 | 0.06% | |
| 2. | 2,264,247 | $1,342,653,186 | 0.25% | |
| 3. | 2,003,742 | $1,188,178,931 | 0.06% | |
| 4. | 1,957,539 | $1,160,781,476 | 0.02% | |
| 5. | 1,843,963 | $1,093,433,180 | 0.04% |
News See All
15 Set-It-and-Forget-It Stocks to Buy in 2026
Long-term wealth building requires choosing investments that could withstand various economic conditions.
H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600
On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $600 while maintaining a Buy rating.
Top 10 Stocks Warren Buffett Would Buy in 2026
Warren Buffett is the legendary founder of Berkshire Hathaway and one of the world's most successful value investors.
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2025 Earnings Call Transcript February 25, 2026United Therapeutics Corporation beats earnings expectations.
United Therapeutics Corporation (UTHR): A Bull Case Theory
We came across a bullish thesis on United Therapeutics Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on UTHR.
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript October 29, 2025United Therapeutics Corporation beats earnings expectations.
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case
United Therapeutics Corporation (NASDAQ:UTHR) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies.
11 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies
Renaissance Technologies has not had the best of runs in an action-filled year that has seen equity markets rally to record highs.
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the top cheap pharmaceutical stocks to buy now. H.C.
Hedge Fund Resource Center